Historical Timeline

Milestones

2011

Onyx receives Fast Track designation for carfilzomib and immediately begins NDA filing process on a rolling basis by submitting the preclinical module

2010

Onyx reports positive complete results from Phase 2b study of single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

Onyx enters into an exclusive agreement valued in excess of $300 million with Ono Pharmaceutical, giving Ono the rights to develop and commercialize carfilzomib and ONX 0912 for all oncology indications in Japan

Phase 3 ASPIRE trial begins, evaluating carfilzomib in combination with lenalidomide (Revlimid) and low-dose dexamethasone in patients with relapsed multiple myeloma

ONX 0912, an oral proteasome inhibitor, enters clinical testing

2009

Onyx acquires Proteolix Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of patients with cancer and autoimmune diseases

Phase 3 DECISION trial begins, evaluating Nexavar in patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer

Onyx and Bayer report positive results from a Phase 2 trial evaluating Nexavar plus the chemotherapeutic agent, capecitabine, in patients with advanced breast cancer

Phase 3 MISSION trial begins, evaluating Nexavar in patients with NSCLC who have failed two or three previous treatments

Phase 2 SPACE trial begins, evaluating Nexavar in combination with TACE

Phase 3 SEARCH trial begins, evaluating Nexavar in combination with Tarceva

2008

Hollings Renton retires as chairman and CEO of Onyx

N. Anthony Coles, M.D., joins Onyx as president and CEO

Nexavar pivotal liver cancer study (SHARP) published in The New England Journal of Medicine

Onyx acquires license to ONX 0801, a novel targeted oncology compound in preclinical development

2007

Nexavar pivotal kidney cancer study (TARGET) published in The New England Journal of Medicine

Nexavar is approved as the first and only targeted therapy for the treatment of patients with unresectable liver cancer

2005

Nexavar is approved for the treatment of patients with advanced kidney cancer; the first new drug in more than a decade to treat this disease, representing a breakthrough in the treatment of kidney cancer

2004

PD 0332991, an oral, cell cycle inhibitor, enters clinical testing

2003

Onyx focuses its efforts solely on the development of sorafenib and discontinues therapeutic virus program

2000

Sorafenib (now Nexavar), an oral targeted therapy, enters clinical testing

1998

Onyx and Warner Lambert, now Pfizer, extend collaboration in area of cell cycle regulation

1996

Frank McCormick leaves Onyx to become head of the University of California, San Francisco Cancer Center and Cancer Research Institute

Onyx completes IPO and is listed on the Nasdaq under stock symbol ONXX

1995

Onyx and Warner Lambert, now Pfizer, form collaboration to develop therapeutics for cell cycle regulation

1994

Onyx and Miles Inc. (predecessor to Bayer HealthCare Pharmaceuticals, Inc.) form collaboration

1993

Onyx appoints Hollings Renton as the company’s first president and CEO

1992

Onyx Pharmaceuticals is founded by Frank McCormick to discover and develop cancer therapeutics and is spun out of the Cetus and Chiron merger as privately held company

1991

Cetus Corporation merges with Chiron Corporation

1985

Frank McCormick, Ph.D., begins cancer research program at Cetus Corporation

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204